| Aktie | Ticker | Breite | GCS | 2025/Q3 | |||
|---|---|---|---|---|---|---|---|
| Investment ($) | QoQ ($) | QoQ (%) | Anz. Fonds | ||||
| 43.047.844 $ | -9.558.842 $ | +35,3 % | 7 | ||||
| Edgewise Therapeutics, Inc. | EWTX | → 0 | Stark | 16.709.211 $ | +3.203.800 $ | +23,7 % | 1 |
| ARVINAS, INC. | ARVN | → 0 | Neutral | 13.510.343 $ | +1.839.436 $ | +15,8 % | 1 |
| Crinetics Pharmaceuticals, Inc. | CRNX | → 0 | Neutral | 5.872.650 $ | +1.817.490 $ | +44,8 % | 1 |
| Cogent Biosciences, Inc. | COGT | → 0 | Neutral | 3.600.985 $ | +1.800.492 $ | +100,0 % | 1 |
| Rallybio Corp | RLYB | → 0 | Stark | 1.647.500 $ | +531.558 $ | +47,6 % | 1 |
| Alector, Inc. | ALEC | → 0 | Neutral | 1.005.124 $ | +529.727 $ | +111,4 % | 1 |
| Passage BIO, Inc. | PASG | → 0 | Neutral | 702.031 $ | -19.281.345 $ | -96,5 % | 1 |
| 43.047.844 $ | -9.558.842 $ | +35,3 % | 7 | ||||